KR20230026458A - Shp2 억제제의 결정형 및 이의 조성물, 제조 방법과 용도 - Google Patents

Shp2 억제제의 결정형 및 이의 조성물, 제조 방법과 용도 Download PDF

Info

Publication number
KR20230026458A
KR20230026458A KR1020237002092A KR20237002092A KR20230026458A KR 20230026458 A KR20230026458 A KR 20230026458A KR 1020237002092 A KR1020237002092 A KR 1020237002092A KR 20237002092 A KR20237002092 A KR 20237002092A KR 20230026458 A KR20230026458 A KR 20230026458A
Authority
KR
South Korea
Prior art keywords
cancer
group
ray powder
powder diffraction
diffraction pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020237002092A
Other languages
English (en)
Korean (ko)
Inventor
치앤강 정
하오 주거
예 자오
Original Assignee
이턴 바이오파마 (상하이) 코., 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이턴 바이오파마 (상하이) 코., 엘티디. filed Critical 이턴 바이오파마 (상하이) 코., 엘티디.
Publication of KR20230026458A publication Critical patent/KR20230026458A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237002092A 2020-06-18 2021-06-17 Shp2 억제제의 결정형 및 이의 조성물, 제조 방법과 용도 Withdrawn KR20230026458A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020096778 2020-06-18
CNPCT/CN2020/096778 2020-06-18
PCT/CN2021/100673 WO2021254449A1 (zh) 2020-06-18 2021-06-17 一种shp2抑制剂的晶型及其组合物、制备方法和用途

Publications (1)

Publication Number Publication Date
KR20230026458A true KR20230026458A (ko) 2023-02-24

Family

ID=79268476

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237002092A Withdrawn KR20230026458A (ko) 2020-06-18 2021-06-17 Shp2 억제제의 결정형 및 이의 조성물, 제조 방법과 용도

Country Status (8)

Country Link
US (1) US20230339975A1 (cg-RX-API-DMAC7.html)
EP (1) EP4169920A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023532217A (cg-RX-API-DMAC7.html)
KR (1) KR20230026458A (cg-RX-API-DMAC7.html)
CN (1) CN115698007A (cg-RX-API-DMAC7.html)
AU (1) AU2021290733A1 (cg-RX-API-DMAC7.html)
CA (1) CA3183063A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021254449A1 (cg-RX-API-DMAC7.html)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3860717A1 (en) * 2018-10-03 2021-08-11 Gilead Sciences, Inc. Imidozopyrimidine derivatives
CN117143079A (zh) * 2018-11-06 2023-12-01 上海奕拓医药科技有限责任公司 一种螺芳环化合物及其应用
JP2022506887A (ja) * 2018-11-07 2022-01-17 シャンハイ リンジーン バイオファーマ カンパニー リミテッド 窒素含有縮合複素環系ｓｈｐ２阻害剤化合物、製造方法及び使用
EP3889153A4 (en) * 2018-11-30 2022-09-07 Tuojie Biotech (Shanghai) Co., Ltd. PYRIMIDINE AND FIVE-MEMBERED HETEROCYCLIC NITROGEN DERIVATIVE, METHOD OF MANUFACTURE THEREOF AND MEDICAL USES THEREOF
US20220073521A1 (en) * 2018-11-30 2022-03-10 Tuojie Biotech (Shanghai) Co., Ltd. Pyrimidine and five-membered nitrogen heterocycle derivative, preparation method therefor, and medical uses thereof
KR20220054285A (ko) * 2019-06-28 2022-05-02 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 피리미딘 5 원 질소 헤테로고리형 유도체, 이의 제조 방법 및 이의 약학적 용도
WO2021088945A1 (zh) * 2019-11-08 2021-05-14 南京圣和药业股份有限公司 作为shp2抑制剂的化合物及其应用
CN113754683A (zh) * 2020-06-05 2021-12-07 上海奕拓医药科技有限责任公司 同位素取代的螺芳环化合物及其应用

Also Published As

Publication number Publication date
EP4169920A1 (en) 2023-04-26
CN115698007A (zh) 2023-02-03
WO2021254449A1 (zh) 2021-12-23
US20230339975A1 (en) 2023-10-26
CA3183063A1 (en) 2021-12-23
AU2021290733A1 (en) 2023-02-23
EP4169920A4 (en) 2024-08-07
JP2023532217A (ja) 2023-07-27

Similar Documents

Publication Publication Date Title
JP6317320B2 (ja) 上皮成長因子受容体キナーゼ阻害剤の塩
CN103261161B (zh) 凝血因子Xa抑制剂的结晶形式
CN101676266B (zh) 氘代的ω-二苯基脲及衍生物以及包含该化合物的药物组合物
JP2015180679A (ja) ナトリウム４−｛［９−クロロ−７−（２−フルオロ−６−メトキシフェニル）−５Ｈ−ピリミド［５，４−ｄ］［２］ベンゾアゼピン−２−イル］アミノ｝−２−メトキシベンゾエートの結晶形
KR20130046436A (ko) 안드로겐 수용체 길항제, 항암제로서 사이클릭 n,n''-다이아릴티오우레아 및 n,n''-다이아릴우레아, 이의 제조방법 및 이의 용도
US20240174669A1 (en) Crystalline forms of a parp1 inhibitor
CN115385894A (zh) 与吡啶酰基哌啶5-ht1f激动剂相关的组合物和方法
CN104245677B (zh) 1‑(3‑叔丁基‑1‑对甲苯基‑1h‑吡唑‑5‑基)‑3‑(5‑氟‑2‑(1‑(2‑羟乙基)‑1h‑吲唑‑5‑基氧基)苯甲基)脲盐酸盐的晶形
WO2023193563A1 (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
EP3315493B1 (en) Phenyl amino pyrimidine compound or polymorph of salt thereof
WO2022063197A1 (zh) 一种嘧啶甲酰胺类化合物及其应用
KR20230026458A (ko) Shp2 억제제의 결정형 및 이의 조성물, 제조 방법과 용도
EP3941472B1 (en) Crystalline and amorphous forms of-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2 <ns1:i>h</ns1:i>?-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof
JP2025509950A (ja) Ｐｉ３ｋ阻害剤の結晶形態及び塩ならびにその製造方法及びその使用方法
KR100909923B1 (ko) Ｎ-(2,3-디메틸-5,6,7,8-테트라히드로푸로[2,3-ｂ]퀴놀린-4-일)-2-(2-옥소피롤리딘-1-일)아세트아미드의 다형체
EP4631937A1 (en) Crystalline form or amorphous form of oxoisoindole-5-formamide compound or salt and solvate thereof
EP2345649A1 (en) Benzimidazole compound in crystal form and salt thereof
RU2792620C2 (ru) Кристаллическая форма ингибитора parp-1 и способ ее получения
WO2024214044A1 (en) Multicomponent complexes, including salts and hydrates and solvates, of inupadenant
HK40086041A (en) Crystalline form of 1-(3-tert-butyl-1-p-tolyl-1h-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-1h-indazol-5-yloxy)benzyl)urea hydrochloride
WO2021228236A1 (zh) 氘代四氢噻吩并[3,4-d]嘧啶二酮化合物以及包含该化合物的药物组合物
BR122024009277A2 (pt) Formas cristalinas de um composto de triazolopirimidina

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230118

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240617

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20250609

WITB Written withdrawal of application